title: Thalidomide improves prevention of chemotherapy-induced gastrointestinal side effects following a modified FOLFOX7 regimen: results of a prospective randomized crossover study.
abstract: OBJECTIVE
  Thalidomide was firstly evaluated for the control of chemotherapy-induced gastrointestinal side effects following a modified FOLFOX7 (mFOLFOX7) regimen.
  
  
  METHODS
  Chemotherapy-naive patients with malignant tumors were randomized into two groups: A-B group (A, 0.3 mg of ramosetron plus 10 mg of dexamethasone on day 1, was given intravenously in the first cycle, and B, 0.3 mg of ramosetron plus 10 mg of dexamethasone on day 1 intravenously plus 150 mg orally twice daily of thalidomide on days 2 through 5, in the second cycle) and B-A group (those drugs were given in the reverse sequence). The primary end point was the efficacy of thalidomide in controlling delayed (days 2 through 5) chemotherapy-induced nausea and vomiting (CINV). The secondary end point was the safety of thalidomide.
  
  
  RESULTS
  Of 52 patients enrolled, 50 patients (96%) were assessable. Complete response rates of delayed nausea (no nausea) were higher with group B than group A (52% vs 24%, P = 0.004 on day 2; 58% vs 24%, P = 0.001 on day 3; and 60% vs 36%, P = 0.016 on day 4). Complete response rates of delayed emesis (no emetic episodes, no rescue therapy) for group B and A also showed significance (86% vs 66%, P = 0.019 on day 2 and 76% vs 56%, P = 0.035 on day 3). Complete response rates on anorexia for group B were higher than those for group A on days 2 through 5. More patients in group B reported sedation or dizziness than in group A (42% vs 9.6%; P = 0.000).
  
  
  CONCLUSIONS
  Thalidomide improves prevention of chemotherapy-induced gastrointestinal side effects following the mFOLFOX7 regimen. It is a safe, effective antiemetic.
authors.affiliation: Department of Medical Oncology, the First Hospital, China Medical University, Shenyang City, China. liuyunpeng@medmail.com.cn
authors.forename: Yunpeng
authors.initials: Y
authors.lastname: Liu
authors.forename: Jingdong
authors.initials: J
authors.lastname: Zhang
authors.forename: Yuee
authors.initials: Y
authors.lastname: Teng
authors.forename: Lingyun
authors.initials: L
authors.lastname: Zhang
authors.forename: Ping
authors.initials: P
authors.lastname: Yu
authors.forename: Bo
authors.initials: B
authors.lastname: Jin
authors.forename: Mingfang
authors.initials: M
authors.lastname: Zhao
authors.forename: Jing
authors.initials: J
authors.lastname: Shi
authors.forename: Shizhou
authors.initials: S
authors.lastname: Liu
authors.forename: Na
authors.initials: N
authors.lastname: Song
authors.forename: Zhi
authors.initials: Z
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D000855:Anorexia / Q000139:chemically induced / Q000517:prevention & control; D000932:Antiemetics / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D018592:Cross-Over Studies; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D041981:Gastrointestinal Tract / Q000187:drug effects*; D006801:Humans; D002955:Leucovorin / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D009944:Organoplatinum Compounds / Q000009:adverse effects; D011446:Prospective Studies; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
chemical_list: D000932:Antiemetics; D009944:Organoplatinum Compounds; D013792:Thalidomide; D002955:Leucovorin; D005472:Fluorouracil